Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Published on February 4, 2014 at 8:33 AM · No Comments

DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies.

XOMA, a California based U.S. public company, focuses its research on allosteric modulation which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. Domain Therapeutics has extensive expertise in allosteric modulation and operates DTect-All(TM), a platform that has successfully discovered small molecule allosteric modulators for a wide range of GPCRs.

Domain Therapeutics and XOMA will jointly evaluate the robustness of DTect-All to identify allosteric modulator antibodies of a first target. If successful, the partners may elect to further collaborate on other GPCRs from a set of preselected targets for which, under the terms of the agreement, Domain Therapeutics will be eligible for an upfront payment and certain undisclosed milestones per target, as well as undisclosed royalties. Domain will have the right to offer its DTect-All platform to discover antibody-based drugs to other companies outside the scope of the set of GPCRs selected by XOMA.

“We strongly believe that XOMA is the partner of choice to discover allosteric modulator antibodies targeting GPCRs and that applying DTect-All to this area of research will represent a real breakthrough,” said Pascal Neuville, board director and CEO of Domain Therapeutics. “We anticipate that this collaboration will enhance our drug discovery capabilities by opening the door to other biologics. It will further strengthen Domain Therapeutics’ position as a key player in GPCR drug discovery.”

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post